A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of Metformin
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
GSK189075
Metformin
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Tolerability, GSK189075,, Metformin,, Safety,, Diabetes,
Eligibility Criteria
Inclusion Criteria:
- Diagnosed with Type 2 Diabetes for at least three months prior to study
- Diabetes treated with metformin only
- Give consent and sign an informed consent form.
- Agree to follow specific requirements of birth control during participation.
Exclusion Criteria:
- Type I Diabetes.
- Treatment with insulin within 3 months prior to screening
- History of diabetic ketoacidosis or lactic acidosis
- Allergy or sensitivity to metformin or similar drugs or any medical conditions which prohibit metformin use
- Excessive blood donation 56 days before the start of the study
- Urinary tract or bladder infections within four weeks of study start
- Alcohol abuse or illicit drug use within 12 months of study start
- Receiving other investigational drugs or participating in other research trials within 30 of the study start
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements with 7-14 days of study start
- Live alone without regular, daily interactions with someone who can be an emergency contact
Sites / Locations
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Placebo Comparator
Experimental
Experimental
Arm Label
Subjects receiving treatment P
Subjects receiving treatment A
Subjects receiving treatment B
Arm Description
Eligible subjects will receive placebo twice daily along with metformin twice daily for 13 days.
Eligible subjects will receive GSK189075 500 milligrams twice daily along with metformin twice daily for 13 days.
Eligible subjects will receive GSK189075 750 milligrams twice daily along with metformin twice daily for 13 days.
Outcomes
Primary Outcome Measures
Clinical laboratory tests, ECGs, physical exam & adverse events:
Home diary of blood sugar results, adverse events and drug dosing.
Secondary Outcome Measures
study drug blood levels:
Blood glucose & insulin levels following oral glucose challenge:
fluid intake & output
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00519480
Brief Title
A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of Metformin
Official Title
A Two-Week, Randomized, Double-Blind, Repeat-Dose, Parallel-Group Study to Evaluate the Safety and Tolerability of Metformin > 2000mg Co-Administered With Either GSK189075 500mg BID or GSK 189075 750mg BID to Subjects With Type 2 Diabetes Mellitus
Study Type
Interventional
2. Study Status
Record Verification Date
September 2017
Overall Recruitment Status
Completed
Study Start Date
September 11, 2007 (Actual)
Primary Completion Date
April 1, 2008 (Actual)
Study Completion Date
April 1, 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
GlaxoSmithKline
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study will assess safety and tolerability of metformin plus GSK189075 in people with Type 2 Diabetes. About 48 people will participate in this study. Volunteers will not know if they are receiving GSK189075 or a placebo. Participation will last about 5 weeks including a run-in period of up to 2 weeks if necessary to increase metformin up to 2000mg daily, a 13-day treatment period, and a follow-up visit about 1 week after the treatment period. Volunteers will remain in the research clinic beginning 2 days before they receive the first dose of GSK189075 until after the morning dose on the fourth day and from the afternoon of the 12th day of dosing until the morning after the last dose. They will have clinic visits on dosing Days 6, 8, and 10. Volunteers will be given equipment and instructions for measuring their blood sugar at home and will be asked to keep a study diary. Blood pressure, heart rate, laboratory tests on blood and urine, physical examinations, reports of drug side effects and ECGs will be obtained during the clinic visits to assess safety.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
Tolerability, GSK189075,, Metformin,, Safety,, Diabetes,
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
50 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Subjects receiving treatment P
Arm Type
Placebo Comparator
Arm Description
Eligible subjects will receive placebo twice daily along with metformin twice daily for 13 days.
Arm Title
Subjects receiving treatment A
Arm Type
Experimental
Arm Description
Eligible subjects will receive GSK189075 500 milligrams twice daily along with metformin twice daily for 13 days.
Arm Title
Subjects receiving treatment B
Arm Type
Experimental
Arm Description
Eligible subjects will receive GSK189075 750 milligrams twice daily along with metformin twice daily for 13 days.
Intervention Type
Drug
Intervention Name(s)
GSK189075
Intervention Description
GSK189075 will be available as an oral tablet with dosing strengths of 500 milligrams and 250 milligrams.
Intervention Type
Drug
Intervention Name(s)
Metformin
Intervention Description
Metformin will be available as an immediate release oral tablet with dosing strengths of 500 milligrams and 850 milligrams.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo will be available as an oral tablets.
Primary Outcome Measure Information:
Title
Clinical laboratory tests, ECGs, physical exam & adverse events:
Time Frame
screening, in-clinic stays, outpatient clinic visits & follow up visit (approximately 50 days)
Title
Home diary of blood sugar results, adverse events and drug dosing.
Time Frame
throughout the study (approximately 50 days)
Secondary Outcome Measure Information:
Title
study drug blood levels:
Time Frame
Dosing Days 1 & 13 metformin blood levels: Days -1 & 13
Title
Blood glucose & insulin levels following oral glucose challenge:
Time Frame
Dosing Days -1 & 13
Title
fluid intake & output
Time Frame
dosing Days -1 - 3, 13
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosed with Type 2 Diabetes for at least three months prior to study
Diabetes treated with metformin only
Give consent and sign an informed consent form.
Agree to follow specific requirements of birth control during participation.
Exclusion Criteria:
Type I Diabetes.
Treatment with insulin within 3 months prior to screening
History of diabetic ketoacidosis or lactic acidosis
Allergy or sensitivity to metformin or similar drugs or any medical conditions which prohibit metformin use
Excessive blood donation 56 days before the start of the study
Urinary tract or bladder infections within four weeks of study start
Alcohol abuse or illicit drug use within 12 months of study start
Receiving other investigational drugs or participating in other research trials within 30 of the study start
Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements with 7-14 days of study start
Live alone without regular, daily interactions with someone who can be an emergency contact
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
GSK Clinical Trials
Organizational Affiliation
GlaxoSmithKline
Official's Role
Study Director
Facility Information:
Facility Name
GSK Investigational Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33169
Country
United States
Facility Name
GSK Investigational Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78209
Country
United States
Facility Name
GSK Investigational Site
City
Buenos Aires
ZIP/Postal Code
1425
Country
Argentina
Facility Name
GSK Investigational Site
City
Berlin
ZIP/Postal Code
14050
Country
Germany
12. IPD Sharing Statement
Citations:
PubMed Identifier
34120651
Citation
Dobbins R, Hussey EK, O'Connor-Semmes R, Andrews S, Tao W, Wilkison WO, Cheatham B, Sagar K, Hanmant B. Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin. BMC Pharmacol Toxicol. 2021 Jun 13;22(1):34. doi: 10.1186/s40360-021-00502-0.
Results Reference
derived
Learn more about this trial
A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of Metformin
We'll reach out to this number within 24 hrs